Are anti-infectious vaccinations safe and effective in patients with autoimmunity

International Reviews of Immunology

Volumn 29, Issue 3, 2010, Pages 270-314

  Salemi, Simonetta ^a   D'Amelio, Raffaele ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Direzione Generale della Sanita Militare   (Italy)

Author keywords

Autoimmune diseases; Insulin dependent diabetes mellitus; Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus; Vaccinations; Vasculitides

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; INFLIXIMAB; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PNEUMOCOCCUS VACCINE; PREDNISONE; RITUXIMAB; RUBELLA VACCINE; SALAZOSULFAPYRIDINE; SWINE INFLUENZA VACCINE; TETANUS TOXOID; THYMOPENTIN; TICK BORNE ENCEPHALITIS VACCINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TYPHOID PARATYPHOID VACCINE; VACCINE;

ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CHRONIC ARTHRITIS; CLINICAL TRIAL; COUGHING; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; EPILEPSY; HUMAN; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA B; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SEIZURE; SEROCONVERSION; SIDE EFFECT; SORE THROAT; SYSTEMIC LUPUS ERYTHEMATOSUS; VACCINATION; VACCINATION REACTION; VASCULITIS; AUTOIMMUNE DISEASES; CHILD; IMMUNOLOGY; INFECTION CONTROL; RISK FACTOR;

AUTOIMMUNE DISEASES; AUTOIMMUNITY; CHILD; COMMUNICABLE DISEASE CONTROL; HUMANS; RISK FACTORS; VACCINATION; VACCINES;

EID: 77953213924     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2010.483028     Document Type: Review

References (132)

1. Gluck T, Muller-Landner U. Vaccination in patients with chronic rheumatic or autoimmune diseases. Clin Infect Dis 2008; 46: 1459-1465.
2. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Developing clinical guidelines. West J Med 1999; 170: 348-351.
3. Davis LE, Hersh EM, Curtis JE, et al. Immune status of patients with multiple sclerosis. Analysis of primary and established immune responses in 24 patients. Neurology 1972; 22: 989-997.
4. Sibley WA, Bamford CR, Laguna JF. Influenza vaccination in patients with multiple sclerosis. JAMA 1976; 236: 1965-1966.
5. Myers LW, Ellison GW, Lucia M, et al. Swine influenza virus vaccination in patients with multiple sclerosis. J Infect Dis 1977; 136: S546-S554.
6. Bamford CR, Sibley WA, Laguna JF. Swine influenza vaccination in patients with multiple sclerosis. Arch Neurol 1978; 35: 242-243.
7. Michielsens B, Wilms G, Marchal G, Carton H. Serial magnetic resonance imaging studies with paramagnetic contrast medium: assessment of disease activity in patients with multiple sclerosis before and after influenza vaccination. Eur Neurol 1990; 30: 258-259.
8. Salvetti M, Pisani A, Bastianello S, et al. Clinical and MRI assessment of disease activity in patients with multiple sclerosis after influenza vaccination. J Neurol 1995; 242: 143-146.
9. Mokhtarian F, Shirazian D, Morgante L, et al. Influenza virus vaccination of patients with multiple sclerosis. Mult Scler 1997; 3: 243-247.
10. Miller AE, Morgante LA, Buchwald LY, et al. A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis. Neurology 1997; 48: 312-314.
11. Keyser J De, Zwanikken C, Boon M. Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis. J Neurol Sci 1998; 159: 51-53.
12. Moriabadi NF, Niewiesk S, Kruse N, et al. Influenza vaccination in MS: Absence of T-cell response against white matter proteins. Neurology 2001; 56: 938-943.
13. Confavreux C, Suissa S, Saddier P, et al. Vaccinations and the risk of relapse in multiple sclerosis. N Engl J Med 2001; 344: 319-326. (Pubitemid 32107639)
14. Schwid SR, Decker MD, Lopez-Bresnahan M, Rebif-Influenza Vaccine Study Investigators. Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a. Neurology 2005; 65: 1964-1966.
15. Keyser J De. Safety of tetanus vaccination in relapsing-remitting multiple sclerosis. Infection 1998; 26: 319.
16. Baumhackl U, Franta C, Retzl J, et al. A controlled trial of tick-borne encephalitis vaccination in patients with multiple sclerosis. Vaccine 2003; 21(Suppl 1):S56-S61.
17. Herroelen L, Keyser J De, Ebinger G. Central-nervous-system demyelination after immunisation with recombinant hepatitis B vaccine. Lancet 1991; 338: 1174-1175.
18. Gout O, Lyon Caen O. Sclerotic plaques and vaccination against hepatitis B. Rev Neurol 1998; 154: 205-207.
19. Williams GW, Steinberg AD, Reinertsen JL, et al. Influenza immunization in systemic lupus erythematosus: A double-blind trial. Ann Int Med 1978; 88: 729-734.
20. Brodman R, Gilfillan R, Glass D, Schur PH. Influenza vaccine response in systemic lupus erythematosus. Ann Int Med 1978; 88: 735-740.
21. Louie JS, Nies KM, Shoji KT, et al. Clinical and antibody responses after influenza immunization in systemic lupus erythematosus. Ann Int Med 1978; 88: 790-792.
22. Ristow SC, Douglas RG, Condemi JJ. Influenza vaccination of patients with systemic lupus erythematosus. Ann Int Med 1978; 88: 786-789.
23. Herron A, Dettleff G, Hixon B, et al. Influenza vaccination in patients with rheumatic diseases. JAMA 1979; 242: 53-56.
24. Turner-Stokes L, Cambridge G, Corcoran T, et al. In vitro response to influenza immunisation by peripheral blood mononuclear cells from patients with systemic lupus erythematosus and other autoimmune diseases. Ann Rheum Dis 1988; 47: 532-535.
25. Turner-Stokes L, Cambridge G, Snaith ML. In vitro lymph node and peripheral blood lymphocyte responses to influenza immunization in patients with systemic lupus erythematosus. Clin Exp Rheumatol 1989; 7: 71-74.
26. Abu-Shakra M, Zalmanson S, Neumann L, et al. Influenza virus vaccination of patients with systemic lupus erythematosus: effects on disease activity. J Rheumatol 2000; 27: 1681-1685.
27. Abu-Shakra M, Press J, Sukenik S, Buskila D. Influenza virus vaccination of patients with SLE: Effects on generation of autoantibodies. Clin Rheumatol 2002; 21: 369-372.
28. Abu-Shakra M, Press J, Varsano N, et al. Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol 2002; 29: 2555-2557.
29. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-640.
30. Mercado U, Acosta H, Avendano L. Influenza vaccination of patients with systemic lupus erythematosus. Rev Invest Clin 2004; 56: 16-20.
31. Holvast A, Huckriede A, Wilschut J, et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis 2006; 65: 913-918.
32. Porto F Del, Laganà B, Biselli R, et al. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity. Vaccine 2006; 24: 3217-3223. Epub 2006 Jan 23.
33. Tarján P, Sipka S, Lakos G, et al. Influenza vaccination and the production of anti-phospholipid antibodies in patients with systemic lupus erythematosus. Scand J Rheumatol 2006; 35: 241-249.
34. Stojanovich L. Influenza vaccination of patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Clin Dev Immunol 2006; 13: 373-375.
35. Stratta P, Cremona R, Lazzarich E, et al. Life-threatening systemic flare-up of systemic lupus erythematosus following influenza vaccination. Lupus 2008; 17: 67-68.
36. Holvast A, Assen S van, Haan A de, et al. Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: An open, prospective, controlled study. Rheumatology 2009; 48: 1294-1299. Epub 2009 Aug 19.
37. Holvast A, Assen S van, Haan A de, et al. Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus. Arthritis Rheum 2009; 60: 2438-2447.
38. Wallin L, Quintilio W, Locatelli F, et al. Safety and efficiency of influenza vaccination in systemic lupus erythematosus patients. Acta Reumatol Port 2009; 34: 498-502.
39. Wisik-Szewczyk E, Romanowska M, Mielnik P, et al. Anti-influenza vaccination in systemic lupus erythematosus patients: An analysis of specific humoral response and vaccination safety. Clin Rheumatol. DOI 10.1007/s10067-010-1373-y
40. Klippel JH, Karsh J, Stahl NI, et al. A controlled study of pneumococcal polysac-charide vaccine in systemic lupus erythematosus. Arthritis Rheum 1979; 22: 1321-1325.
41. Jarrett MP, Schiffman G, Barland P, Grayzel AI. Impaired response to pneu-mococcal vaccine in systemic lupus erythematosus. Arthritis Rheum 1980; 23: 1287-1293. (Pubitemid 11234046)
42. McDonald E, Jarret MP, Schiffman G, Grayzel AI. Persistence of pneumococcal antibodies after immunization in patients with systemic lupus erythematosus. J Rheumatol 1984; 11: 306-308.
43. Croft SM, Schiffman G, Snyder E, et al. Specific antibody response after in vivo antigenic stimulation in systemic lupus erythematosus. J Rheumatol 1984; 11: 141-146.
44. Lipnick RN, Karsh J, Stahl NI, et al. Pneumococcal immunization in patients with systemic lupus erythematosus treated with immunosuppressives. J Rheumatol 1985; 12: 1118-1122.
45. Battafarano DF, Battafarano NJ, Larsen L, et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum 1998; 41: 1828-1834.
46. Tarján P, Sipka S, Maródi L, et al. No short-term immunological effects of Pneu-mococcus vaccination in patients with systemic lupus erythematosus. Scand J Rheumatol 2002; 31: 211-215.
47. Elkayam O, Paran D, Caspi D, et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis 2002; 34: 147-153. Epub 2001 Dec 4.
48. Elkayam O, Paran D, Burke M, et al. Pneumococcal vaccination of patients with systemic lupus erythematosus: Effects on generation of autoantibodies. Autoim-munity 2005; 38: 493-496.
49. Pisoni C, Sarano J, Benchetrit G, et al. Antipneumococcal vaccination in patient with systemic lupus erythematosus. Medicina 2003; 63: 388-392. (Pubitemid 37407949)
50. Moxey-Mims MM, Preston K, Fivush B, McCurdy F. Heptavax-B in pediatric dialysis patients: Effect of systemic lupus erythematosus. Chesapeake Pediatric Nephrology Study Group. Pediatr Nephrol 1990; 4: 171-173.
51. Fleming SJ, Moran DM, Cooksley WG, Faoagali JL. Poor response to a re-combinant hepatitis B vaccine in dialysis patients. J Infect 1991; 22: 251-257.
52. Gartner S, Emlen W. HBV vaccination of SLE patients [abstract]. Arthritis Rheum 1996; 39(Suppl. 9):S291.
53. Senécal JL. Severe exacerbation of systemic lupus erythematosus after hepatitis B vaccination and importance of pneumococcal vaccination in patients with autosplenectomy: Comment on the article by Battafarano et al. Arthritis Rheum 1999; 42: 1304-1308.
54. Maillefert JF, Sibilia J, Toussirot E, et al. Rheumatic disorders developed after hepatitis B vaccination. Rheumatology 1999; 38: 978-983.
55. Kuruma KA, Borba EF, Lopes MH, et al. Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus. Lupus 2007; 16: 350-354.
56. Devey ME, Bleasdale K, Isenberg DA. Antibody affinity and IgG subclass of responses to tetanus toxoid in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol 1987; 68: 562-569.
57. Kashef S, Ghazizadeh F, Derakhshan A, et al. Antigen-specific antibody response in juvenile-onset SLE patients following routine immunization with tetanus toxoid. Iran J Immunol 2008; 5: 181-184.
58. Chalmers A, Scheifele D, Patterson C, et al. Immunization of patients with rheumatoid arthritis against influenza: A study of vaccine safety and immuno-genicity. J Rheumatol 1994; 21: 1203-1206.
59. Cimmino MA, Seriolo B, Accardo S. Influenza vaccination in rheumatoid arthritis. J Rheumatol 1995; 22: 1802-1803.
60. Francioni C, Rosi P, Fioravanti A, et al. Vaccination against influenza in patients with rheumatoid arthritis: Clinical and antibody response. Recenti Prog Med 1996; 87: 145-149.
61. Iyngkaran P, Limaye V, Hill C, et al. Rheumatoid vasculitis following influenza vaccination. Rheumatology 2003; 42: 907-909.
62. Fomin I, Caspi D, Levy V, et al. Vaccination against influenza in rheumatoid arthritis: The effect of disease modifying drugs, including TNF a blockers. Ann Rheum Dis 2006; 65: 191-194.
63. Kapetanovic MC, Saxne T, Nilsson JA, Geborek P. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology 2007; 46: 608-611.
64. Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007; 34: 272-279.
65. Kubota T, Nii T, Nanki T, et al. Anti-tumor necrosis factor therapy does not diminish the immune response to influenza vaccine in Japanese patients with rheumatoid arthritis. Mod Rheumatol 2007; 17: 531-533. Epub 2007 Dec 20.
66. Gelinck LB, van der bijl AE, Beyer WE, et al. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis 2008; 67: 713-716. Epub 2007 Oct 26.
67. Elkayam O, Bashkin A, Mandelboim M, et al. The effect of Infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2009 Feb 24. [Epub ahead of print]
68. Salemi S, Picchianti-Diamanti A, Germano V, et al. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: Safety and immunogenicity. Clin Immunol 2010; 134: 113-120. Retrieved 20 Oct 2009.
69. Nii T, Kubota T, Nanki T, et al. Reevaluation of antibody titers 1 year after influenza vaccination in patients with rheumatoid arthritis receiving TNF blockers. Mod Rheumatol 2009; 19: 216-218. Epub 2008 Nov 18.
70. Gelinck LB, Teng YK, Rimmelzwaan GF, et al. Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 2007; 66: 1402-1403.
71. Oren S, Mandelboim M, Braun-Moscovici Y, et al. Vaccination against influenza in patients with rheumatoid arthritis: The effect of rituximab on the humoral response. Ann Rheum Dis 2008; 67: 937-941. Epub 2007 Nov 2.
72. van Assen S, Holvast A, Benne CA, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with Rituximab. Arthritis Rheum 2010; 62: 75-81.
73. O'Dell JR, Gilg J, Palmer W, et al. Pneumococcal vaccine in rheumatoid arthritis. J Clin Rheumatol 1996; 2: 59-63.
74. Elkayam O, Caspi D, Reitblatt T, et al. The effect of tumour necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2004; 33: 283-288.
75. Kapetanovic MC, Saxne T, Sjoholm A, et al. Influence of methotrexate, TNF-blockers and prednisolone on antibody responses to pneumococcal vaccine in patients with rheumatoid arthritis. Rheumatology 2006; 45: 106-111.
76. Visvanathan S, Keenan GF, Baker DG, et al. Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. J Rheumatol 2007; 34: 952-957.
77. Gelinck LBS, Van Der Biji AE, Visser LG, et al. Synergistic immunosuppres-sive effect of anti-TNF combined with methotrexate on antibody responses to the 23-valent pneumococcal polysaccharide vaccine. Vaccine 2008; 26: 3528-3533.
78. Bingham CO III, Looney RJ, Deodhar A, et al. Immunization response in rheumatoid arthritis patients treated with Rituximab. Results from a controlled clinical trial. Arthritis Rheum 2010; 62: 64-74.
79. Karsh JB, Pavlidis N, Schiffman G, Moutsopoulos HM. Immunization of patients with Sjogren syndrome with pneumococcal polysaccharide vaccine. Arthritis Rheum 1980; 23: 1294-1297.
80. Palit J, Chattopadhyay C, Malaviya AN, et al. Some immunological parameters in rheumatoid arthritis from India. Biomedicine 1977; 27: 70-73.
81. Elkayam O, Yaron M, Caspi D. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. Ann Rheum Dis 2002; 61: 623-625.
82. Pozzilli P, Gale E, Visalli N, et al. The immune response to influenza vaccination in diabetic patients. Diabetologia 1986; 29: 850-854.
83. Diepersloot R, Bouter K, Beyer W, et al. Humoral immune response and delayed type hypersensitivity to influenza vaccine in patients with diabetes mellitus. Dia-betologia 1987; 30: 397-401.
84. Diepersloot RJ, Bouter KP, van Beek R, et al. Cytotoxic T-cell response toinfluenza A subunit vaccine in patients with type 1 diabetes mellitus. Neth J Med 1989; 35: 68-75.
85. Ruben FL, Fireman P, Porte RE La, et al. Immune responses to killed influenza vaccine in patients with type 1 diabetes. Altered responses associated with HLA-DR3 and DR4. J Lab Clin Med 1998; 41: 1828-1834.
86. El-Madhun AS, Cox RJ, Seime A, et al. Systemic and local immune responses after parenteral influenza vaccination in juvenile diabetic patients and healthy controls: Results from a pilot study. Vaccine 1998; 16: 156-160.
87. Zuccotti GV, Scaramuzza A, Riboni S, et al. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus. Vaccine 2009; 27: 5357-5362. Epub 2009 Jul 14.
88. Kostinov MP, Skochilova TV, Vorob'eva VA, et al. Autoantibodies after vaccination against pneumococcal and influenza infections in children and adolescents with type I diabetes mellitus. Zh Mikrobiol Epidemiol Immunobiol 2009; 2: 53-57.
89. Pozzilli P, Arduini P, Visalli N, et al. Reduced protection against hepatitis B virus following vaccination in patients with Type 1 (insulin-dependent) diabetes. Diabetologia 1987; 30: 817-819.
90. Pagani S, Cruciani L, Chianelli M, et al. Thymopentin administration and increase of seroconversion after B-hepatitis vaccine in diabetic patients. Diabetes Res 1989; 12: 199-201. (Pubitemid 20144380)
91. Wismans PJ, Hattum J van, Gast G de, et al. A prospective study of in vitro anti-HBs producing B cells (spot-ELISA) following primary and supplementary vaccination with a recombinant hepatitis B vaccine in insulin dependent diabetic patients and matched controls. J Med Virol 1991; 35: 216-222.
92. Bouter KP, Diepersloot RJ, Wismans PJ, et al. Humoral immune response to a yeast-derived hepatitis B vaccine in patients with type 1 diabetes mellitus. Diabet Med 1992; 9: 66-69.
93. Volti S Li, Caruso-Nicoletti M, Biazzo F, et al. Hyporesponsiveness to intradermal administration of hepatitis B vaccine in insulin dependent diabetes mellitus. Arch Dis Child 1998; 78: 54-57.
94. Arslanoǧlu I, Cetin B, Işgüven P, Karavuş M. Anti-HBs response to standard hepatitis B vaccination in children and adolescents with diabetes mellitus. J Pediatr Endocrinol Metab 2002; 15: 389-395.
95. Kostinov MP Tarasova AA. Intensity of immunity in children with type 1 diabetes mellitus vaccinated against hepatitis B. Zh Mikrobiol Epidemiol Immunobiol 2008; 5: 61-65.
96. Eibl N, Spatz M, Fischer GF, et al. Impaired primary immune response in type-1 diabetes: Results from a controlled vaccination study. Clin Immunol 2002; 103: 249-259.
97. Tarasova AA, Kostinov MP, Iastrebova NE, Skochilova TV. Effect of vaccination against pneumococcal infection in children with type 1 diabetes mellitus. Zh Mikro-biol Epidemiol Immunobiol 2007; 6: 45-49.
98. Malleson PN, Tekano JL, Scheifele DW, Weber JM. Influenza immunization in children with chronic arthritis: A prospective study. J Rheumatol 1993; 20: 1769-1773.
99. Olson NY, Lindsley CB. Influenza immunization in children with chronic arthritis. J Rheumatol 1994; 21: 1581-1582.
100. Kanakoudi-Tsakalidou F, Trachana M, Pratsidou-Gertsi P, et al. Influenza vaccination in children with chronic rheumatic diseases and long-term immunosup-pressive therapy. Clin Exp Rheumatol 2001; 19: 589-594.
101. Kasapçopur O, Cullu F, Kamburoǧlu-Goksel A, et al. Hepatitis B vaccination in children with juvenile idiopathic arthritis. Ann Rheum Dis 2004; 63: 1128-1130.
102. Zonneveld-Huijssoon E, Ronaghy A, Van Rossum MA, et al. Safety and efficacy of meningococcal c vaccination in juvenile idiopathic arthritis. Arthritis Rheum 2007; 56: 639-646.
103. Heijstek MW, Pileggi GC, Zonneveld-Huijssoon E, et al. Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis. Ann Rheum Dis 2007; 66: 1384-1387. Epub 2007 Feb 6. (Pubitemid 47492487)
104. Borte S, Liebert UG, Borte M, Sack U. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology 2009; 48: 144-148. Epub 2008 Dec 11.
105. Korematsu S, Miyahara H, Kawano T, et al. A relapse of systemic type juvenile idiopathic arthritis after a rubella vaccination in a patient during a long-term remission period. Vaccine 2009; 27: 5041-5042. Epub 2009 Jul 2.
106. Damjanov I, Amaid J. Progression of renal disease in Henoch-Shönlein purpura after influenza vaccination. JAMA 1979; 242: 255.
107. Cannata J, Cuesta V, Peral V, et al. Reactivation of vasculitis after influenza vaccination. Br Med J 1981; 283: 526.
108. Mormile R, D'Alterio V, Treccagnoli G, Sorrentino P. Henoch-Shönlein purpura with anti-phospholipid antibodies after influenza vaccination: How fearful is it in children? Vaccine 2004; 23: 567-568.
109. Zycinska K, Romanowska M, Nowak I, et al. Antibody response to inactivated subunit influenza vaccine in patients with Wegener's granulomatosis. J Physiol Pharmacol 2007; 58: 819-828.
110. Stassen PM, Sanders JF, Kallenberg CGM, Stegeman CA. Influenza vaccination does not result in an increase in relapses in patients with ANCA-associated vas-culitis. Nephrol Dial Transplant 2008; 23: 654-658. Epub 2007 Oct 2.
111. Birck R, Kaelsch I, Schnuelle P, et al. ANCA-associated vasculitis following influenza vaccination: Causal association or mere coincidence? J Clin Rheumatol 2009; 15: 289-291.
112. Holvast A, Stegeman CA, Benne CA, et al. Wegener's granulomatosis patients show an adequate antibody response to influenza vaccination. Ann Rheum Dis 2009; 68: 873-878.
113. Erkek E, Ayaslioglu E, Erkek AB, et al. Response to vaccination against hepatitis B in patients with Behcet's disease. J Gastroenterol Hepatol 2005; 20: 1508-1511.
114. Zinman L, Thoma J, Kwong JC, et al. Safety of influenza vaccination in patients with myasthenia gravis: A population-based study. Muscle Nerve 2009; 40: 947-951.
115. Benz R, Krause R, Taverna C. Immune thrombocytopenic purpura reactivation after tick-borne encephalitis vaccination. Vaccine 2009; 27: 5172-5173.
116. Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, October 2007-September 2008. Ann Intern Med 2008; 147: 725-729.
117. Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2009. Ann Intern Med 2008; 150: 40-44.
118. Bridges MJ, Coady D, Kelly CA, et al. Factors influencing uptake of influenza vaccination in patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62: 685.
119. Fahy WA, Farnworth E, Yeldrem KP, et al. Pneumococcal and influenza vaccination in patients with rheumatic conditions and receiving DMARD therapy. Rheumatology 2006; 45: 912-913.
120. Pradeep J, Watts R, Clunie G. Audit on the uptake of influenza and pneumococcal vaccination in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 837-838.
121. Sowden E, Mitchell W. An audit of influenza and pneumococcal vaccination in rheumatology outpatients. BMC Musculoskelet Disord 2007; 8: 58.
122. Ledwich LJ, Harrington TM, Ayoub WT, et al. Improved influenza and pneumo-coccal vaccination in rheumatology patients taking immunosuppressants using an electronic health record best practice alert. Arthritis & Rheumatism 2009; 61: 1505-1510. DOI 10.1002/art.24873
123. Maya R, Gershwin ME, Shoenfeld Y. Hepatitis B virus (HBV) and autoimmune disease. Clinic Rev Allerg Immunol 2008; 34: 85-102. DOI 10.1007/s12016-007- 8013-6
124. Girard M. Autoimmune hazards of hepatitis B vaccine. Autoimmunity Reviews 2005; 4: 96-100.
125. MMWR. Measles, Mumps, and Rubella - Vaccine Use and Strategies for Elimination of Measles, Rubella, and Congenital Rubella Syndrome and Control of Mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP). 1998; 47(RR-8):1-57.
126. Kuroda Y, Nacionales DC, Akaogi J, et al. Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine. Biomed Pharmacother 2004; 58: 325-337.
127. Brezinschek HP, Hofstaetter T, Leeb BF, et al. Immunization of patients with rheumatoid arthritis with anti-tumour necrosis factor therapy and methotrexate. Curr Opin Rheumatol 2008; 20: 295-299.
128. Monto AS, Ohmit SE, Petrie JG, et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med. 2009; 361: 1260-1267.
129. Cornu C, Yzebe D, Leophonte P, et al. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: A meta-analysis of randomized trials. Vaccine 2001; 19: 4780-4790.
130. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: A review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009; 9: 493-504.
131. Maruyama T, Taguchi O, Niederman MS, et al. Efficacy of 23-valent pneumo-coccal vaccine in preventing pneumonia and improving survival in nursing home residents: Double blind, randomised and placebo controlled trial. BMJ 2010; 340: c1004. DOI:10.1136/bmj.c1004
132. MMWR. Recommended adult immunization schedule - United States 2009. 2009; 57: Q-1-Q-4.